These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7028075)

  • 1. Variations in the opsonic requirements of group B streptococcus type III.
    Hastings MJ; Easmon CS
    Br J Exp Pathol; 1981 Oct; 62(5):519-25. PubMed ID: 7028075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opsonization of group B Streptococcus type III: studies using clinical strains and maternal sera.
    Hastings MJ; Neil J; Easmon CS
    Br J Exp Pathol; 1985 Jun; 66(3):317-23. PubMed ID: 3890914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the opsonic and complement triggering activity of human monoclonal IgG1 and IgM antibody against group B streptococci.
    Shyur SD; Raff HV; Bohnsack JF; Kelsey DK; Hill HR
    J Immunol; 1992 Mar; 148(6):1879-84. PubMed ID: 1541826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type III group B streptococcal strain differences in susceptibility to opsonization with human serum.
    Fischer GW; Hunter KW; Wilson SR
    Pediatr Res; 1981 Dec; 15(12):1525-9. PubMed ID: 7033908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstration of opsonic and protective activity of human cord sera against type III group B streptococcus that are independent of type-specific antibody.
    Kim KS; Wass CA; Hong JK; Concepcion NF; Anthony BF
    Pediatr Res; 1988 Nov; 24(5):628-32. PubMed ID: 3060825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opsonic activity of human IgG and IgM antibody for type III group B streptococci.
    Anthony BF; Concepcion NF
    Pediatr Res; 1989 Oct; 26(4):383-7. PubMed ID: 2677951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An IgA monoclonal antibody directed against type III antigen on group B streptococci acts as an opsonin.
    Bohnsack JF; Hawley MM; Pritchard DG; Egan ML; Shigeoka AO; Yang KD; Hill HR
    J Immunol; 1989 Nov; 143(10):3338-42. PubMed ID: 2681414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of complement component C1q in the IgG-independent opsonophagocytosis of group B streptococcus.
    Butko P; Nicholson-Weller A; Wessels MR
    J Immunol; 1999 Sep; 163(5):2761-8. PubMed ID: 10453019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic variability of X-protein expression by mastitis-causing Streptococcus agalactiae of serotype NT/X and opsonic activities of specific antibodies.
    Rainard P; Sarradin P; Poutrel B
    Microb Pathog; 1994 May; 16(5):359-72. PubMed ID: 7815919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strain specificity of opsonins for group B streptococci types II and III.
    Shigeoka AO; Hall RT; Hill HR
    Infect Immun; 1979 Feb; 23(2):438-45. PubMed ID: 370017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of antibody and complement in opsonization of group B streptococci.
    Shigeoka AO; Hall RT; Hemming VG; Allred CD; Hill HR
    Infect Immun; 1978 Jul; 21(1):34-40. PubMed ID: 101462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-independent and -dependent opsonization of group B Streptococcus requires the first component of complement C1.
    Levy NJ; Kasper DL
    Infect Immun; 1985 Jul; 49(1):19-24. PubMed ID: 3891622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ingestion and killing of Streptococcus agalactiae by bovine granulocytes in the presence of natural opsonins.
    Rainard P; Lautrou Y; Poutrel B
    Vet Microbiol; 1988 Sep; 18(1):41-50. PubMed ID: 3055659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunoglobulins for intravenous use: comparison of available preparations for group B streptococcal antibody levels, opsonic activity, and efficacy in animal models.
    Givner LB
    Pediatrics; 1990 Dec; 86(6):955-62. PubMed ID: 2123536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired phagocytosis and opsonisation towards group B streptococci in preterm neonates.
    Källman J; Schollin J; Schalèn C; Erlandsson A; Kihlström E
    Arch Dis Child Fetal Neonatal Ed; 1998 Jan; 78(1):F46-50. PubMed ID: 9536841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neonatal cellular and humoral immunity to group B streptococci.
    Hill HR; Shigeoka AO; Hall RT; Hemming VG
    Pediatrics; 1979 Nov; 64(5 Pt 2 Suppl):787-94. PubMed ID: 388335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin therapy of neonatal group B streptococcal infections: an overview.
    Fischer GW
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S13-6. PubMed ID: 3041355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci.
    Baltimore RS; Kasper DL; Baker CJ; Goroff DK
    J Immunol; 1977 Feb; 118(2):673-8. PubMed ID: 65433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between human neutrophils and group B streptococci (GBS) and group antigens, monitored by Luminol-dependent chemiluminescence.
    Kowolik MJ; Cumming CG; Grant M
    J Clin Lab Immunol; 1982 May; 8(1):55-8. PubMed ID: 7047747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of differences in antibody and complement requirements on phagocytic uptake and intracellular killing of "c" protein-positive and -negative strains of type II group B streptococci.
    Payne NR; Kim YK; Ferrieri P
    Infect Immun; 1987 May; 55(5):1243-51. PubMed ID: 3552996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.